Strategic question
Which ventures across digital biomarkers, DTx, genomics and teleconsultation are mature enough to enable non-fluid underwriting?
How Galen Growth helped
From market signal to decision-ready evidence
Powered by HealthTech Alpha, we mapped two priority ecosystems, evaluated 291 ventures against underwriter-grade criteria and co-built a prioritised shortlist anchored to the client’s operational requirements.
Outcomes
Converted a fragmented HealthTech landscape into a clean, underwriter-relevant set of partnership options.
Decision enabled: Enabled the re-insurer to advance partnership evaluation with a qualified, criteria-matched shortlist.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Sourcing OMICS Ventures to Shape Oncology and Wellness Strategy
Which OMICS-led ventures tackling oncology and wellness are mature enough to partner with an enterprise insurer?
Pressure-Testing a Digital Health Partnership Before Commitment
How does our preferred venture partner compare against credible alternatives in the same market and therapeutic focus?
Helping an APAC Insurer Prioritise Markets, Categories and Venture Targets
Which APAC markets, therapeutic areas and Digital Health categories should we prioritise to accelerate regional growth?